SEMAL

Semal Therapeutics is a preclinical-stage biotechnology company dedicated to developing transformative small molecule therapies for neurodegenerative diseases by targeting the Integrated Stress Response (ISR). The company's primary focus is on modulating eIF2B, a critical regulator of protein synthesis that becomes impaired under cellular stress, leading to neuronal death in conditions such as Amyotrophic Lateral Sclerosis (ALS) and Vanishing White Matter Disease. By restoring eIF2B function and cellular proteostasis, Semal aims to halt the progression of neurodegeneration. Founded by industry veterans and backed by top-tier venture capital firms, the company is advancing a pipeline of novel candidates toward clinical development.